GGrantIndex
← Leaderboards

Tatsuo Kawai

Massachusetts General Hospital

$13,661,886
Attributed
$16,018,794
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,018,794 · 11

By mechanism

R01$6,921,088 · 3
U19$4,052,971 · 3
U01$3,224,166 · 1
R21$1,142,615 · 3
R56$677,954 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Organ Transplantation

Research focus

Organ TransplantationBone Marrow TransplantationNonhuman PrimateKidney AllograftChimerismRegimenConditioningProtocols DocumentationAllograft ToleranceTransplantationTransplant RecipientsClinical ApplicationKidneyCellsModalityHematopoieticNovel StrategiesMaintenanceKidney TransplantationAllograftingResponseAllogenicClinical TrialsBase

Grant awards (23)

Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates$1,845,438
R01 · FY2025 · AI · contact PI
Targeting innate immunity for induction of robust renal allograft tolerance$1,074,143
U01 · FY2025 · AI · contact PI
Project 1: Translating Renal Xenotransplantation$892,862
U19 · FY2025 · AI · contact PI
Targeting innate immunity for induction of robust renal allograft tolerance$1,074,783
U01 · FY2024 · AI · contact PI
Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates$922,719
R01 · FY2024 · AI · contact PI
Targeting innate immunity for induction of robust renal allograft tolerance$1,075,240
U01 · FY2023 · AI · contact PI
Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates$922,719
R01 · FY2023 · AI · contact PI
Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primates$922,719
R01 · FY2022 · AI · contact PI
Mcl-1 inhibition for induction of hematopoietic chimerism without nonselective myeloablative treatments in nonhuman primates$203,795
R21 · FY2022 · AI · contact PI
Mcl-1 inhibition for induction of hematopoietic chimerism without nonselective myeloablative treatments in nonhuman primates$245,795
R21 · FY2021 · AI · contact PI
Inhibition of Bcl-2 for Induction of Mixed Chimerism and Renal Allograft Tolerance Without Myelosuppression$677,954
R56 · FY2018 · AI · contact PI
Inhibition of BCL-2 for induction of mixed chimerism without myelosuppressive conditioning$210,200
R21 · FY2017 · AI · contact PI
Tolerance of Kidney and Islet Transplants via the Mixed Chimerism Approach$573,942
U19 · FY2016 · AI · contact PI
Inhibition of BCL-2 for induction of mixed chimerism without myelosuppressive conditioning$251,175
R21 · FY2016 · AI · contact PI
Tolerance of Kidney and Islet Transplants via the Mixed Chimerism Approach$650,945
U19 · FY2015 · AI · contact PI
Tolerance of Kidney and Islet Transplants via the Mixed Chimerism Approach$635,457
U19 · FY2014 · AI · contact PI
Tolerance of Kidney and Islet Transplants via the Mixed Chimerism Approach$656,119
U19 · FY2013 · AI · contact PI
Tolerance of Kidney and Islet Transplants via the Mixed Chimerism Approach$643,646
U19 · FY2012 · AI · contact PI
Optimizing Mixed-Chimerism for Heart Transplantation in Non-Human Primates$752,796
R01 · FY2010 · HL
Optimizing Mixed-Chimerism for Heart Transplantation in Non-Human Primates$736,855
R01 · FY2009 · HL
MIXED CHIMERISM AND TOLERANCE IN CYNOMOLGUS MONKEYS$408,921
R01 · FY2005 · AI
MIXED CHIMERISM AND TOLERANCE IN CYNOMOLGUS MONKEYS$408,921
R01 · FY2004 · AI
MIXED CHIMERISM AND TOLERANCE IN CYNOMOLGUS MONKEYS$231,650
R21 · FY2000 · AI